Rigosertib sodium
sodium 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetate
Molecular Identity
Rigosertib sodium
sodium 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetate
PubChem CID: 23696523
Rigosertib sodium is the sodium salt of rigosertib. It is an anti-cancer agent which has been granted Orphan Drug Designation by the FDA for use in patients with myelodysplastic syndromes (MDS). It has a role as an EC 2.7.11.21 (polo kinase) inhibitor, an antineoplastic agent, a microtubule-destabilising agent and an apoptosis inducer. It contains a rigosertib(1-).
2D Structure
Properties
C21H24NNaO8S
Molecular Formula
473.50
Molecular Weight
g/mol
473.1120
Exact Mass
Da
132
TPSA
Good oral absorption (< 140 A²)
1
H-Bond Donors
9
H-Bond Acceptors
684
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
Rigosertib sodium592542-60-4EstybonNovonexON-01910 sodiumON01910 sodiumON 01910.NaON 01910 sodiumON 01910 sodium saltSyB C-1101ON-01910.Na406FL5G00VCHEBI:145421RefChem:930770Polo-like kinase 1 Inhibitor ON 01910.Na
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Rigosertib sodium
Loading drug network...